The New England journal of medicine, 2019-01, Vol.380 (4), p.335-346
2019
Details
- Autor(en) / Beteiligte
- Titel
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
- Ist Teil von
- The New England journal of medicine, 2019-01, Vol.380 (4), p.335-346
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Among patients with thrombotic thrombocytopenic purpura, the addition of caplacizumab, an anti–von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment, to daily plasma exchange resulted in faster platelet recovery, fewer TTP-related deaths, and fewer recurrences and thromboembolic events.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1806311Titel-ID: cdi_proquest_journals_2170526121
- Format
- –
- Schlagworte
- ADAMTS13 Protein - metabolism, Adolescent, Adult, Aged, Anemia, Autoimmune diseases, Body Mass Index, Double-Blind Method, Double-blind studies, Fees & charges, Female, Fibrinolytic Agents - adverse effects, Fibrinolytic Agents - therapeutic use, Gingival Diseases - chemically induced, Health risk assessment, Hemolytic anemia, Hemorrhage - chemically induced, Humans, Intention to Treat Analysis, Intravenous administration, Ischemia, Male, Middle Aged, Monoclonal antibodies, Patients, Plasma, Plasma Exchange, Platelet Count, Platelets, Purpura, Purpura, Thrombotic Thrombocytopenic - drug therapy, Purpura, Thrombotic Thrombocytopenic - mortality, Purpura, Thrombotic Thrombocytopenic - therapy, Single-Domain Antibodies - adverse effects, Single-Domain Antibodies - therapeutic use, Thrombocytopenia, Thrombocytopenic purpura, Thromboembolism, Thrombosis, Thrombotic thrombocytopenic purpura, Von Willebrand factor, von Willebrand Factor - antagonists & inhibitors, Young Adult